- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of October 23
The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of October 23.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 23.
Number 5: Novartis credits stronger-than-expected sales of its biosimilars for strong third-quarter net income.
Number 4: Etanercept has been shown to significantly reduce overall healthcare utilization for patients with rheumatoid arthritis, especially for patients who are highly compliant with therapy.
Number 3: New evidence suggests that anti—tumor necrosis factor agents could be repurposed to treat depression that is unresponsive to existing therapies.
Number 2: The FDA has released new educational materials on biosimilars. The resources, geared toward clinicians, include webinars, staff presentations, graphics, and sharable social media assets.
Number 1: The RAND corporation has released a new report on biosimilars, estimating that the United States could save $54 billion over the next 10 years by using biosimilars.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Top 5 Most-Read Policy Articles of 2024
December 28th 2024The top biosimilar policy articles of 2024 highlight advancements that include FDA guidance to simplify biosimilar interchangeability and CMS drug price negotiations under the Inflation Reduction Act, alongside challenges posed by pharmacy benefit manager rebate practices and the need for more active stakeholder engagement.
